HONG KONG, Aug. 17, 2018 /PRNewswire/ -- Global Cord
Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),
China's leading provider of cord
blood collection, laboratory testing, hematopoietic stem cell
processing, and stem cell storage services, today announced the
results of the scrip dividend elections. The election period during
which the Company provided to all of its shareholders the option to
elect to receive, in cash or ordinary shares of the Company, a
dividend payment of US$0.08 per share
ended at Noon Eastern Daylight Time
on August 16, 2018. During the
election period, of the 120,824,742 ordinary shares of the Company
outstanding as of July 30, 2018, the
record date, holders of 87,523,354 ordinary shares notified the
Company of their election to receive the dividend in the form of
ordinary shares of the Company.
As a result of these elections, the Company will issue a total
of 726,333 ordinary shares and consequently the Company's
outstanding ordinary shares will
consist of a total of 121,551,075 ordinary shares. The delivery of
the newly issued ordinary shares as well as the payment of the cash
distribution is expected to occur on August
20, 2018.
For more information regarding the scrip dividend, please visit
the Company's website at
http://ir.globalcordbloodcorp.com/phoenix.zhtml?c=206671&p=irol-dividends.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, and
Section 21E of the Securities Exchange Act of 1934. These
statements relate to future events or the Company's future
financial performance. The Company has attempted to identify
forward-looking statements by terminology including "anticipates",
"believes", "expects", "can", "continue", "could", "estimates",
"intends", "may", "plans", "potential", "predict", "should" or
"will" or the negative of these terms or
other comparable terminology. These statements are only
predictions, uncertainties and other factors may cause the
Company's actual results, levels of activity, performance or
achievements to be materially different from any future results,
levels of activity, performance or achievements expressed or
implied by these forward-looking statements. The information in
this press release is not intended to project future performance of
the Company. Although the Company believes that the expectations
reflected in the forward-looking statements are reasonable, the
Company does not guarantee future results, levels of activity,
performance or achievements. The Company expectations are as of the
date this press release is issued, and the Company does not intend
to update any of the forward-looking statements after the date this
press release is issued to conform these statements to actual
results, unless required by law.
About Global Cord Blood Corporation
Global Cord Blood Corporation is the first and largest umbilical
cord blood banking operator in China in terms of geographical coverage and
the only cord blood banking operator with multiple licenses.
Under current People's Republic of
China government regulations, only one licensed cord blood
banking operator is permitted to operate in each licensed region
and no new licenses will be granted before 2020 in addition to the
seven licenses authorized as of today. Global Cord Blood
Corporation provides cord blood collection, laboratory testing,
hematopoietic stem cell processing, and stem cell storage
services. For more information, please visit our website at
http://www.globalcordbloodcorp.com.
For more information, please contact:
Global Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@globalcordbloodcorp.com
ICR, Inc.
Mr. William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: William.zima@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/global-cord-blood-corporation-announces-the-results-of-scrip-dividend-elections-300698739.html
SOURCE Global Cord Blood Corporation